Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 1997

View Archived Issues

Coulter: Q3 1997 highlights

Faulding: Q1 1998 highlights

CoCensys: Q3 1997 highlights

SIBIA Neurosciences: Q3 1997 highlights

Pharmacopeia: Q3 and nine-month 1997 highlights

Protein C and sepsis

ILEX Oncology: Q3 1997 highlights

Boehringer Ingelheim to acquire Ben Venue; new company formed

Cell Genesys reports delivery of erythropoietin gene therapy

New azole antifungals from Zambon/Isagro

Profile of Green Cross's rHSA

Gastric prokinetic agents under development at Janssen

Three new launches anticipated for Pfizer in 1998

Akzo Nobel prepares two series of thrombin inhibitors

Korean researchers describe new ginseng saponins with antitumor activity

Roussel Uclaf reports new erythromycin antibiotics

Peripherally acting opioid analgesics described by Astra

U.S. approval for Raxar

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

PEG-hirudin compared to established antithrombotic agents

Nyotran compared to other antifungals in vitro

SPA-S-843 compared in experimental infection models to current antifungals

Merck to develop Vical technology for therapeutic vaccines

Preclinical activity and pharmacokinetic data presented for UR-9825

Saruplase efficacy demonstrated in large patient study

Myriad creates CNS database for potential drug discovery

Gensia Sicor terminates collaboration with Atrix

Apomorphine designated orphan drug

ReoPro cleared in U.S. for expanded labeling

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...